

April 4, 2003

## Loss from Revaluation of Securities for the Fiscal Year Ended March 31, 2003

Ono Pharmaceutical Co., Ltd. today announced that the market value of the securities investments held by the Company fell significantly at the end of March 2003, and the Company would write off the following amounts, which are considered unlikely to recover.

### 1. Total Loss from Revaluation of Securities for the Fiscal Year Ended March 31, 2003

Total loss from revaluation of securities for the fiscal year ended March 31, 2003 (A)	7,165 million yen
Amount of net assets for the fiscal year ended March 31, 2002 (B)	303,261 million yen
$(A)/(B) \times 100$	2.4%
Ordinary profit for the fiscal year ended March 31, 2002 (C)	51,538 million yen
$(A)/(C) \times 100$	13.9%
Net profit for the fiscal year ended March 31, 2002 (D)	22,396 million yen
$(A)/(D) \times 100$	32.0%

Note: The above figures represent the nonconsolidated financial figures.

### 2. Future Prospect

The Company will record the above revaluation loss on securities as extraordinary expense for the fiscal year ended March 31, 2003. In-house work is now going on to compile the business performance of the fiscal year ended March 31, 2003.

#### Corporate Information:

Corporate name : Ono Pharmaceutical Co., Ltd.  
Representative : Toshio Ueno, Chairman and CEO  
Stock code : 4528  
Stock listings : First sections of Tokyo Stock Exchange and Osaka Securities Exchange  
Inquiries : Kinya Morimoto, Director, Public Relations  
Tel. : +81-6-6222-5551  
Fax : +81-6-6222-2875